For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Peptide Bioregulator
Vesugen
A short synthetic peptide from the Khavinson bioregulator series, investigated in preclinical models for peptide signaling in vascular endothelial tissue.
Quantity
$59.99
Bundle & save
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2 business days
Overnight shipping available
Free shipment protection included
Vesugen
1 × 20mg · $59.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
About Vesugen
Structure and research context
Vesugen is a synthetic tripeptide from the Khavinson bioregulator series with the sequence Lys-Glu-Asp (KED). It consists of an N-terminal lysine followed by glutamic acid and aspartic acid, giving a short peptide with one basic and two acidic side chains. The KED sequence is one of the more frequently studied tripeptides from this research group and appears in cell-culture work on vascular endothelial cells, fibroblasts, mesenchymal stem cells and neuroendocrine tissue.
Vesugen in the research literature
In vascular endothelial cell cultures, the KED tripeptide was studied for its effects on endothelin-1, connexin and sirtuin-1 expression. Vesugen was also reported to increase the proliferation marker Ki-67 in late-passage endothelial and tissue-specific cultures, and docking modeled its contact with a CATC site in the MKI67 core promoter.
In prostatic fibroblast cultures, Vesugen increased expression of the differentiation factor CXCL12. In fetal bone marrow mesenchymal stem cells, KED modulated expression of IGF1, FOXO1, TNKS2 and NFκB, and in organotypic pineal cultures it was reported to increase Ki-67 and reduce p53 expression.
Summarized from peer-reviewed literature for research context only; not a product claim. PubMed: 28539025 · 25051766 · 22808515 · 32399807 · 22977872
Vesugen Certificate of Analysis
Third-party tested · Independent analytical lab
20mg
99.76%latest
| Tested | Measured | Purity |
|---|---|---|
| Apr 2026 | 22.04mg | 99.76% |
| Mar 2026 | 21.63mg | 99.88% |
| Dec 2025 | 21.61mg | 99.85% |
| Oct 2025 | 22.48mg | 99.49% |
Frequently researched together
Commonly studied alongside Vesugen.
Compound information
Technical specifications
Molecular profile
| Type | Synthetic tripeptide bioregulator |
| Amino acids | 3 |
| Sequence | Lys-Glu-Asp |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Vesugen sources & references
Peer-reviewed literature, for research context
- Advances in gerontology = Uspekhi gerontologii
[Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]
2016·PMID: 28539025Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VK, Dyakonov MM
View source - Advances in gerontology = Uspekhi gerontologii
[The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people]
2014·PMID: 25051774Kitachev KV, Sazonov AB, Kozlov KL, Petrov KIu, Sliusarev AS, Khavinson VKh
View source
More in Bioregulator
Every Bioregulator research compound in the catalog.
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.